- Publisher
CABI - Published
20th May 2013 - ISBN 9781845938079
- Language English
- Pages 296 pp.
- Size 6.875" x 9.75"
Tuberculosis is a global health threat and the unique features of Mycobacterium tuberculosis and emergence of drug-resistant strains highlight the challenge it presents. Covering a wealth of state-of-the-art knowledge from active international experts, this book captures the latest developments in the advent of bacteriological, immunological and molecular tools for diagnosis and the development of new drugs. It shows how the challenge of tuberculosis is currently being met, providing insight into the evidence base underlying new developments in diagnosis, drug development and treatment.
Section1: Diagnosis
1. Improving on microscopy in resource poor settings.
2. The role of molecular tools in diagnosis of tuberculosis.
3. Improving on the LJ slope - automated liquid culture.
4. Phenotypic methods for antibiotic susceptibility testing.
5. Interferon gamma assays in diagnosis and contact tracing.
6. Measuring Immunological responses in the lung - the correct target?
7. Genotypic measures of antibiotic susceptibility.
8. Sniffing out TB
Section 2: Biomarkers for monitoring therapy
1. Lipid bodies and fas1 expression.
2. Measuring gene expression by qPCR.
3. Transcriptomic approaches to mapping responses to drug therapy.
4. Modelling of responses to treatment.
5. Monitoring therapy by bacterial load.
Section 3: Treatment
1. The new drugs pipeline.
2. Clinical Trails for tuberculosis treatment - the challenge.
3. SQ109 - clinical evaluation of a new drug.
4. Rifamicins re-visited.
5. QAB - a new paradigm for a new drug?